FDA has lifted the clinical hold on Tenaya’s MyPEAK-1 Phase 1b/2a trial of TN-201 in MYBPC3-associated hypertrophic cardiomyopathy, with no new safety signals flagged since the data and safety monitoring board endorsed continued enrollment earlier this year. The company reports that cohort management has enabled shorter durations and lower cumulative exposure to prophylactic prednisone and sirolimus even at the higher vector dose tested, and that 52-week follow-up for the first cohort and interim 12- and 26-week readouts from the second cohort have been disclosed.
The core development is operational, not mechanistic: Tenaya will resume dosing once participating sites implement protocol amendments that standardize patient monitoring and immunosuppression management. The steroid and sirolimus agents remain the same; what changes is timing, dosing practices, and surveillance procedures that Tenaya adopted during dose escalation and has now codified. MyPEAK-1 is an open-label, multi-center study evaluating single-dose AAV9-based MYBPC3 gene replacement at 3E13 and 6E13 vg/kg in adults with obstructive or nonobstructive disease, with dose expansion planned.
The strategy here reflects the current gene therapy playbook in a stricter regulatory era: keep the regimen conceptually simple, lock down variability at sites, and make risk mitigation auditable. By formalizing an immunosuppression protocol that already trended to lower cumulative exposure amid dose escalation, Tenaya is signaling to FDA that it can manage AAV9’s immune liabilities without escalating complexity. This is a defensive and enabling move at once—defensive because cardiac AAV programs are under high scrutiny, enabling because predictable site behavior is often the fastest route off a hold and back to dose expansion.
For stakeholders on the ground, the implications are immediate. Sites will need to reconsent, retrain, and reactivate with standardized steroid and mTOR inhibitor workflows, including tighter therapeutic drug monitoring, infection vigilance, and pre-specified thresholds for dose adjustments. Pharmacy and cardiology teams should expect more regimented scheduling and lab cadence, which can reduce investigator discretion but improve cross-site consistency. Sponsors and CROs gain a clearer operating model for safety oversight and data aggregation, particularly for immunogenicity, transaminase monitoring, and vector-associated adverse events. Screen failure rates will remain a gating factor given pre-existing anti-AAV9 antibodies in adults, so central screening logistics and patient funnel management will be decisive for enrollment velocity. Regulators get a cleaner throughline from dose, exposure, and monitoring to outcomes, which is increasingly a prerequisite for adult AAV programs proceeding into expansion.
What matters next is whether the emerging signal holds with scale. The field will look for sustained MyBP-C restoration markers, effects on LV mass and hypercontractility, and alignment with functional endpoints that can support a registrational path in a genetically defined HCM subset. Manufacturing and lot release at adult-scale vector doses will influence cadence as much as site readiness. The company does not expect a timeline hit, but reactivation cycles, holiday IRB calendars, and drug product availability are practical risks. Watch for the timing of dose re-initiation, the size and pace of expansion cohorts, and any shift toward pediatric planning given the rare pediatric designation. More broadly, this restart will test whether standardized immunosuppression and monitoring can satisfy FDA’s evolving expectations for cardiac AAV, and whether a single-dose gene replacement can carve out clinical and operational space alongside phenotype-modifying therapies in HCM.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
